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ABSTRACT
The heterologous antiviral efficiency of bacterially produced human interferon (Hu-
IFN«2) in the bovine species was studied, using vaccinia infection as experimental model.
In a double blind experiment, young calves were intramuscularly injected daily for seven
consecutive days with different doses of Hu-IFNa2 or placebo, the treatment starting 24 h
before intradermal inoculation of vaccinia virus. A clear protection by interferon was ob¬
served in all the IFN treated animals, although individual variations in the sensitivity to
IFN were recorded. The efficiency of treatment varied according to the dose of IFN used:
With the highest dose (106 IU/kg), complete protection could be obtained.
The only side-effect observed was hyperthermia. Circulating antiviral activity appeared
quite early after each IFN injection, presented a more or less biphasic kinetics, and was
completely cleared after 24 h, justifying the daily treatment schedule. The first evidence of
an in vivo antiviral effect of human interferon in the bovine species opens broad perspec¬
tives for a future use of interferon in veterinary medicine. '
INTRODUCTION
In veterinary medicine, viral diseases cause important economic losses, especially in cattle.Therefore, a broad spectrum antiviral compound would be of high interest to improve the overall
efficiency of bovine production. Interferon seems a very promising candidate for such purposes.11'
However, bovine interferon was not yet available in sufficient amounts to test its antiviral activity
in vivo.
Since the recombinant DNA technology allowed large scale production of different types of
human interferon (for review, see Ref. 2), numerous clinical studies using these molecules as anti-
tumor or antiviral agents in man have been undertaken.
Bacterially produced human a2 interferon (HuIFNa2),(3> one of the subtypes of human leukocyte
interferon, has been shown for the first time to exert an in vivo antiviral activity against experimental
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vaccinia infection in rhesus monkeys.(4> Furthermore, different human interferons,(56> including
Hu-IFNa2,<7) are highly active in bovine cell cultures.
Therefore, the in vivo antiviral effect of Hu-IFNa2 in the bovine species was tested using intra¬
dermal inoculation of vaccinia virus. Indeed, this experimental system produces in calves skin lesions
allowing quantification of interferon activity.
MATERIALS AND METHODS
a) Interferon
Bacterially produced human alpha interferon Hu-IFNa2 was kindly supplied by Dr. C. Weiss-
mann and Dr. M. Fountoulakis from Zürich University. Its specific activity was 10s IU/mg of pro¬
tein and it only contained 5.5 ng of pyrogen/108 IU.
b) Virus
Vaccinia virus, strain ELSTREE (used for the production of human vaccine in Belgium), was
titrated on chorio-allantoic membrane of embryonated hen's eggs and suspended in a glycerin con¬
taining buffer to a final concentration of 108 PFU/ml.
c) Experimental procedure
A double blind experiment was performed (Table 1). Twelve two- to three-week-old calves, from
different origins, were maintained in the IHE quarantine stable, to avoid spreading of vaccinia virus.
Hu-IFNa2 at different doses, or phosphate buffer saline for control animals, in a volume of 0.5 ml,
was intramuscularly injected daily for seven consecutive days, starting on day -1.
Table 1. Data on Experimental Animals and Their Treatment.
Calf
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ANTIVIRAL EFFECT OF HUMAN IFN IN CALVES
At day 0, all the animals except two (11 and 12) were intradermally inoculated with vaccinia virus
preparation, on a shaved area of the flank, using a bifurcated needle; the two uninfected calves were
inoculated by the same way, but with glycerin buffer only.
Plasma samples for the determination of circulating antiviral activity were collected at 0, 30 min, 2
h, and thereafter every 3 h until 24 h after the first administration of interferon, and 0, 30 min, 2, 5,
8, and 24 h after each of the following injections. Body temperature was measured just before each
blood sampling. Skin lesions were daily scored for their size, number, appearance, and degree of
evolution and photographed. Serum samples from days 0 and 15 were taken for anti-vaccinia anti¬
bodies determination.
d) Interferon titration
Circulating antiviral activity was determined by the classical technique of reduction of cytopathic
effect of VSV in human HEp-2 cells. ""
e) Seroneutralization test
Sera from days 0 and 15 were tested for the presence of antibodies against vaccinia virus by inhibi¬
tion of pock formation induced by this virus on chorio-allantoic membrane of embryonated hen's
eggs.
RESULTS
Two calves (5 and 12) were in poor condition at the beginning of the experiment. Both of them
died on day 0; the necropsy revealed cachexia, anemia, and chronic lesions of arthritis and pneu¬
monia, reflecting a severe bacterial systemic infection prior to interferon treatment. The experiment
was therefore performed with ten calves only.
a) Vaccinia lesions
The three untreated control calves (Fig. 1) showed a very similar evolution of vaccinia lesions. A
clear protection by interferon was observed in all the treated animals: lesions developed more slowly
and remained significantly smaller. Figure 2 shows the aspect of skin lesions on day 9, in two control
and two IFN-treated animals.
The diameter of skin lesions appeared to be a good criteria to evaluate the efficiency of IFN treat¬
ment. As shown in Fig. 1, the inhibition of vaccinia lesions development depended on the IFN dose
injected. However, important individual differences appeared in the sensitivity to IFN treatment.
For example, in calf 3, no skin lesions at all could be observed, while calf 4, treated with the same
IFN dose (106 IU/kg) developed small vesicles (Fig. 3).
b) Side effects
IFN treatment was well tolerated by all the animals. However, hyperthermia was recorded in the
treated calves following each IFN injection.
c) Pharmacokinetics ofplasma interferon
Figure 4 gives the evolution of circulating antiviral activity in five treated calves during the 24 h
























































INTERFERON DOSE ( million IU/kg )
FIG. 1. Vaccinal lesions size. The total surface of the vaccinia lesions (34 virus inoculation sites in
each case) was measured by planimetry eight days after infection.
FIG. 2. Skin lesions nine days after infection. a,b: control calves (a = calf number 7, b = calf
















































ANTIVIRAL EFFECT OF HUMAN IFN IN CALVES
JSHHK
FIG. 3. Effect of 106 U/kg IFN treatment on two different calves, a: calf number 3, b: calf number
4.
TIME AFTER INJECTION ( hours )
FIG. 4. Pharmacokinetics of interferon. The circulating antiviral activity was titrated in HEp2
cells.
 
calf 7 (control), · calf 4 (106 IU IFN/kg), O calf 8 (0.5 106 IU IFN/kg), D calf 6 (0.2 106 IU
IFN/kg),  calf 12 (106 IU IFN/kg),  calf 5 (106 IU/kg). The last animals died on day 0 from pre¬

















































treatment; IFN appeared in plasma of the treated animals as early as 30 min after the first injection.
The kinetics presented a biphasic aspect: a first peak was observed 2 h PI (postinjection); the level of
IFN activity decreased until 5 to 8 h PI, increased again to reach a second peak about 11 h PI, and
then returned progressively to undetectable levels after 14 to 17 h. Untreated controls never showed
any detectable circulating antiviral activity.
The level of IFN recovered from plasma was related to the dose initially injected, despite some in¬
dividual variations. Particularly, calves 5 and 12, which died the following day, did not present the
expected titer of circulating antiviral activity.
The pharmacokinetics pattern observed after each of the following IFN injections appeared very
similar, although blood samples were collected only for 8 h PI (data not shown).
d) Seroconversion
None of the twelve calves possessed anti-vaccinia antibodies at the beginning of the experiment.
Neutralizing antibodies against vaccinia virus appeared on day 15 in the sera of all the inoculated
animals, except calf 3, the only one which showed no skin lesions.
DISCUSSION
Bacterially produced Hu-IFNa2 is clearly active against experimental vaccinia infection in calves(Figs. 1 and 2). Moreover, the absence of seroconversion in calf 3 confirms the evidence of a strong
inhibition of virus multiplication by interferon. This confirms the results obtained in a similar pre¬
liminary experiment performed on two calves."10'
However, there are important individual variations in the sensitivity to IFN treatment (Figs. 2 and
3). Although a significant reduction of skin lesions was observed for each dose tested (Fig. 1), 106
IU/kg seems the minimal dose able to confer a complete protection. After the end of the seven day
treatment, no further development of lesions was seen contrary to what is described after a shorter
(two days) treatment in the previously reported study.'10 '"
IFN treatment is well tolerated by all the animals: the only side effect is the classical hyperthermia
described in most studies with exogenous interferon,'1213) except that realized in rhesus monkeys by
Schellekens and coworkers.'4' As the interferon preparation used was highly purified and only con¬
tained 5.5 ng of pyrogen per 108 IU, this transient hyperthermia seems to be provided by interferon
itself.
Circulating interferon activity appeared quite early: a first peak was observed 2 to 5 h after injec¬
tion. This agrees with the numerous pharmacokinetics studies realized following intramuscular in¬
jection of human alpha interferon in different species.'14"1" After a transient decrease, a second
peak is observed 8 to 11 h PI (Fig. 4). In most previous studies, data are only reported for 5 to 8 h
after injection. However, Breinig and coworkers'17' followed the level of circulating antiviral activity
during 24 h in a human patient repeatedly treated with conventionally prepared human a interferon:
These authors observed a very similar biphasic kinetics of circulating interferon, with a first peak
4-5 h and a second one 9-11 h after each IM injection.
No further circulating antiviral activity is detected 24 h PI. This confirms the results of our pre¬
liminary experiment in calves'918' and of most previous studies.'14"16' Breinig et al.,'17' however, still
observed low levels of plasma interferon 24 h PI, but no more at 48 h PI. Similarly, Jordan and co-
workers'19' have shown that leukocyte interferon injected intramuscularly in patients with malig¬
nancy complicated by disseminated herpes zoster, is not completely eliminated in 24 h. They have
also shown that repeated injections cause a progressive rise of the average peak level indicative of an
accumulation of interferon in tissues. Whether this is indicative of a slower degradation of inter¬
feron in the homologous species or of different pharmacokinetics properties for the different inter¬















































ANTIVIRAL EFFECT OF HUMAN IFN IN CALVES
observation made in mice by Sarkar'201 showing that Hu-IFNa, is cleared from the circulation more
rapidly than the mixture of human interferons produced in leukocytes.
As, in our case, interferon was completely cleared from the circulation after 24 h, the daily treat¬
ment schedule adopted seems convenient19' and is recommended for further studies using exogenous
interferon in the bovine species.
Although the level of circulating interferon recovered in treated animals varies according to the
dose injected, as already reported by Schellekens et al.,'4' some individual variations were observed.
Particularly, in the two ill animals (5 and 12), who died the following day, the expected level of
plasma antiviral activity was not recovered. This raises the interesting possibility that trapping of cir¬
culating interferon can occur at the site of the already developed lesions. Further investigations are
needed to substantiate such an interpretation.
In conclusion, this is the first complete report of an efficient protection against a viral infection in
cattle obtained by a way other than classical vaccination. Interferon appears therefore very promis¬
ing as a broad spectrum antiviral compound in veterinary medicine. Some recent findings support
this opinion: The evidence of a role of endogenous interferon in the control of experimental rota¬
virus diarrhea in newborn calves'21·22' and the curative effect of orally administered bovine inter¬
feron in cats suffering from feline leukemia virus-induced non-regenerative anemia.'23' Moreover,
Hu-IFNa2 is active in vitro against several viruses responsible for important economical losses in ani¬
mal production: infectious bovine rhinotracheitis virus (BHV1), pseudorabies virus (SHV1),'24' and
bovine rotavirus (unpublished data).
On the other hand, the calf may represent a convenient model for the in vivo study of the action of
interferon against natural viral infections.
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